• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原位和浸润性乳腺癌的生物功能特征。

Biofunctional characteristics of in situ and invasive breast carcinoma.

机构信息

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, FC, Italy.

出版信息

Cell Oncol (Dordr). 2013 Jul;36(4):303-10. doi: 10.1007/s13402-013-0135-7. Epub 2013 Jun 27.

DOI:10.1007/s13402-013-0135-7
PMID:23807750
Abstract

PURPOSE

The increasing use of breast-conserving surgery makes it essential to identify biofunctional profiles responsible for the progression of in situ to invasive carcinomas to facilitate the detection of lesions that are most likely to relapse or progress and, thus, to be able to offer patients tailored treatment options. Our objective was to analyse and compare biofunctional profiles in ductal carcinomas in situ (DCIS) and invasive ductal carcinomas (IDC). We also aimed to identify markers in tumor and normal surrounding tissues that may be predictive of locoregional recurrence in patients with DCIS.

METHODS

Biofunctional parameters including mitotic activity, estrogen receptor, progesterone receptor, microvessel density (MVD), c-kit and p27 expression were evaluated in 829 in situ and invasive carcinomas. The impact of the biomarker profiles of DCIS, IDC and normal surrounding tissues on loco-regional recurrence was analyzed.

RESULTS

A progressive increase in cell proliferation and a concomitant decrease in steroid hormone receptor-positive lesions was observed during the transition from in situ to invasive carcinomas, as also within each subgroup as grade increased. Conversely, p27 expression and MVD dramatically decreased during the transition from in situ to invasive carcinomas. Finally, we found that a low c-kit expression was indicative of IDC relapse.

CONCLUSIONS

Cell proliferation, hormonal and differentiation characteristics differed in DCIS with respect to IDC, and the main variation in the transition between the two histologic lesions was the decrease in p27 expression and MVD.

摘要

目的

保乳手术的应用日益广泛,因此有必要确定导致原位癌进展为浸润性癌的生物功能特征,以便发现最有可能复发或进展的病变,从而为患者提供针对性的治疗选择。我们的目的是分析和比较导管原位癌(DCIS)和浸润性导管癌(IDC)的生物功能特征。我们还旨在确定肿瘤和正常周围组织中的标志物,这些标志物可能对 DCIS 患者的局部区域复发具有预测性。

方法

评估了 829 例原位癌和浸润性癌中的生物功能参数,包括有丝分裂活性、雌激素受体、孕激素受体、微血管密度(MVD)、c-kit 和 p27 的表达。分析了 DCIS、IDC 和正常周围组织的生物标志物特征对局部区域复发的影响。

结果

从原位癌到浸润性癌的转变过程中,细胞增殖逐渐增加,而甾体激素受体阳性病变同时减少,每个分级组内也存在这种情况。相反,p27 表达和 MVD 在从原位癌到浸润性癌的转变过程中急剧下降。最后,我们发现低 c-kit 表达提示 IDC 复发。

结论

与 IDC 相比,DCIS 中的细胞增殖、激素和分化特征存在差异,两种组织学病变之间的主要变化是 p27 表达和 MVD 的减少。

相似文献

1
Biofunctional characteristics of in situ and invasive breast carcinoma.原位和浸润性乳腺癌的生物功能特征。
Cell Oncol (Dordr). 2013 Jul;36(4):303-10. doi: 10.1007/s13402-013-0135-7. Epub 2013 Jun 27.
2
Is there a low-grade precursor pathway in breast cancer?乳腺癌是否存在低度恶性前体途径?
Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.
3
Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.人表皮生长因子受体 2 阳性导管原位癌患者后续原位和浸润性乳腺癌的风险。
Ann Oncol. 2015 Apr;26(4):682-687. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18.
4
Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.乳腺密度、闪烁乳腺(99m)Tc(V)DMSA 摄取和降钙素基因相关肽(CGRP)在混合浸润性导管癌伴广泛原位导管癌(IDC+DCIS)和纯浸润性导管癌(IDC)中的表达:与雌激素受体(ER)状态、增殖指数 Ki-67 和组织学分级的相关性。
Breast Cancer. 2011 Oct;18(4):286-91. doi: 10.1007/s12282-009-0192-y. Epub 2010 Feb 9.
5
Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.乳腺导管癌中雌激素受体、孕激素受体及c-erbB2癌基因蛋白表达的改变
Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.
6
Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.Nudix 基序 2 在人乳腺癌中的表达:与细胞增殖相关的强预后因子。
Int J Cancer. 2011 Apr 15;128(8):1770-82. doi: 10.1002/ijc.25505.
7
Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.细胞角蛋白标志物、雌激素受体α(ER-α)、孕激素受体(PR)、人表皮生长因子受体2/neu(HER-2/neu)和表皮生长因子受体(EGFR)在乳腺单纯导管原位癌(DCIS)及合并浸润性导管癌(IDC)的DCIS中的表达。
Ann Clin Lab Sci. 2007 Spring;37(2):127-34.
8
Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.乳腺导管癌中 ER、PR、HER-2/neu 和 P53 蛋白表达的改变及其临床意义。
Med Oncol. 2010 Sep;27(3):747-52. doi: 10.1007/s12032-009-9279-8. Epub 2009 Aug 6.
9
Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.原发性导管原位癌(DCIS)与相应局部病变之间乳腺癌受体的克隆性改变。
Eur J Cancer. 2014 Feb;50(3):517-24. doi: 10.1016/j.ejca.2013.10.020. Epub 2013 Nov 22.
10
Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors.浸润性导管癌中bcl2表达的下调既依赖雌激素和孕激素受体,又与不良预后因素相关。
Pathol Oncol Res. 2002;8(1):26-30. doi: 10.1007/BF03033697.

引用本文的文献

1
Ductal Carcinoma Biology, Biomarkers, and Diagnosis.导管癌生物学、生物标志物与诊断
Front Oncol. 2017 Oct 23;7:248. doi: 10.3389/fonc.2017.00248. eCollection 2017.
2
Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.犬浸润性乳腺肿瘤作为人类乳腺癌模型。第 1 部分:自然病史和预后因素。
Breast Cancer Res Treat. 2018 Feb;167(3):635-648. doi: 10.1007/s10549-017-4548-2. Epub 2017 Oct 30.
3
Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid.

本文引用的文献

1
Is there 'progression through grade' in ductal invasive breast cancer?导管内浸润性乳腺癌是否存在“分级进展”?
Breast Cancer Res Treat. 2012 Oct;135(3):693-703. doi: 10.1007/s10549-012-2195-1. Epub 2012 Aug 12.
2
Long-term outcome in patients with ductal carcinoma in situ treated with breast-conserving therapy: implications for optimal follow-up strategies.保乳治疗的导管原位癌患者的长期预后:对最佳随访策略的影响。
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e305-12. doi: 10.1016/j.ijrobp.2011.12.092. Epub 2012 Mar 13.
3
A study to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma.
肌上皮乳腺癌细胞和管腔型乳腺癌细胞对全反式维甲酸表现出不同的反应。
Cell Oncol (Dordr). 2015 Aug;38(4):289-305. doi: 10.1007/s13402-015-0230-z. Epub 2015 Jun 5.
4
New biomarkers to predict the evolution of in situ breast cancers.预测原位乳腺癌进展的新型生物标志物。
Biomed Res Int. 2014;2014:159765. doi: 10.1155/2014/159765. Epub 2014 Aug 26.
一项研究旨在探讨 p27 和细胞周期蛋白 E 免疫表达作为早期乳腺癌预后因素的作用。
World J Surg Oncol. 2011 Mar 16;9:31. doi: 10.1186/1477-7819-9-31.
4
p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.p27Kip1 是预测他莫昔芬治疗反应的因素,但不是绝经前乳腺癌患者的预后标志物。
Int J Cancer. 2010 Dec 15;127(12):2851-8. doi: 10.1002/ijc.25297.
5
Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.乳腺癌中c Kit的定量免疫组化表达可预测患者的预后。
Br J Cancer. 2009 Jul 7;101(1):48-54. doi: 10.1038/sj.bjc.6605113. Epub 2009 Jun 9.
6
Chromosomal alterations associated with the transition from in situ to invasive breast cancer.与原位乳腺癌向浸润性乳腺癌转变相关的染色体改变。
Ann Surg Oncol. 2008 Sep;15(9):2519-25. doi: 10.1245/s10434-008-0051-7. Epub 2008 Jul 12.
7
Expression of c-kit proto-oncogene product in breast tissue.c-kit原癌基因产物在乳腺组织中的表达。
Breast J. 2004 Jul-Aug;10(4):323-7. doi: 10.1111/j.1075-122X.2004.21351.x.
8
Ductal carcinoma in situ, complexities and challenges.导管原位癌:复杂性与挑战
J Natl Cancer Inst. 2004 Jun 16;96(12):906-20. doi: 10.1093/jnci/djh164.
9
Molecular profiling of breast cancer: clinical implications.乳腺癌的分子特征分析:临床意义
Br J Cancer. 2004 Mar 22;90(6):1120-4. doi: 10.1038/sj.bjc.6601667.
10
c-kit and SCF expression in normal and tumor breast tissue.c-kit和SCF在正常及肿瘤乳腺组织中的表达。
Breast Cancer Res Treat. 2004 Jan;83(1):33-42. doi: 10.1023/B:BREA.0000010694.35023.9e.